Latest news with #RVO
Globe and Mail
5 days ago
- Business
- Globe and Mail
Retinal Vein Occlusion Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's 'Retinal Vein Occlusion Pipeline Insight 2025' report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Retinal Vein Occlusion pipeline landscape. It covers the Retinal Vein Occlusion pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Retinal Vein Occlusion pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Retinal Vein Occlusion Pipeline. Dive into DelveInsight's comprehensive report today! @ Retinal Vein Occlusion Pipeline Outlook Key Takeaways from the Retinal Vein Occlusion Pipeline Report In May 2025, Bayer conducted a study treatment intravitreal (IVT) aflibercept is given as an injection into the eye. It works by blocking VEGF and this can help repair vision problems related to RVO. IVT aflibercept is already available and is prescribed by doctors as the standard of care treatment for macula edema secondary to RVO. Standard of care is a treatment that medical experts consider most appropriate for a disease. In May 2025, EyeBiotech Ltd announced a Phase 1/2a 2-part Study Consisting of an Open-label Multiple Ascending Dose (MAD) Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion (BRVO), and a Dose-finding, Double-masked, Comparative Safety, and Preliminary Efficacy Study of Intravitreal (IVT) EYE201 (Tiespectus) in Participants With Either Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD). DelveInsight's Retinal Vein Occlusion Pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Retinal Vein Occlusion treatment. The leading Retinal Vein Occlusion Companies such as Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys and others. Promising Retinal Vein Occlusion Pipeline Therapies such as Ranibizumab, RFB002, Dexamethasone, pegaptanib sodium, AKB-9778, Aflibercept, Bevacizumab and others. Stay ahead with the most recent pipeline outlook for Retinal Vein Occlusion Treatment. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Retinal Vein Occlusion Treatment Drugs Retinal Vein Occlusion Emerging Drugs Profile KSI-301: Kodiak sciences The therapeutic candidate KSI-301, currently in clinical development, is a novel anti-VEGF biologic designed to have an extended ocular half-life. Ischemia due to vein occlusion results in secretion of vascular endothelial growth factor (VEGF) that causes further vascular leakage and edema. Anti-VEGF agents have become a very common treatment to improve the clinical outcomes in patients with RVO. As in wet AMD, an intensive treatment frequency is required to achieve optimal outcomes with currently-approved anti-VEGFs agents. However, many patients are lost to follow up due to the frequent injections and real-world outcomes in RVO do not meet the promise shown in clinical trials. By extending the on-mechanism treatment interval, KSI-301 may relieve the high treatment burden for patients, their family members, and physicians. KSI-301 is being developed in Phase III stage of development towards a once every two months or longer treatment regimen. 601: Sunshine Guojian Pharmaceutical 601A is a recombinant humanized anti-VEGF monoclonal antibody for injection. The proposed main indications are age-related macular degeneration and diabetic macular edema and retinal vein occlusion; and it is currently in Phase II clinical trials. IBE-814: Ripple Therapeutics IBE-814 is designed to deliver a low, consistent, efficacious dose for approximately six to nine months. The goal is to extend clinical benefit while decreasing common steroid-induced adverse events. RIPPLE-1 is a phase II, multi-center, single-masked dose-ranging study designed to evaluate the safety and efficacy of two dosage regimens of IBE-814 IVT in patients with diabetic macular edema (DME) or macular edema due to retinal vein occlusion (RVO). The Retinal Vein Occlusion Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Retinal Vein Occlusion with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Retinal Vein Occlusion Treatment. Retinal Vein Occlusion Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Retinal Vein Occlusion Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Retinal Vein Occlusion Market Explore groundbreaking therapies and clinical trials in the Retinal Vein Occlusion Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Retinal Vein Occlusion Drugs Retinal Vein Occlusion Companies Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys and others. Retinal Vein Occlusion pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Parenteral Intravitreal Subretinal Topical. Molecule Type Retinal Vein Occlusion Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Product Type Unveil the future of Retinal Vein Occlusion Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Retinal Vein Occlusion Market Drivers and Barriers Scope of the Retinal Vein Occlusion Pipeline Report Coverage- Global Retinal Vein Occlusion Companies- Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys and others. Retinal Vein Occlusion Pipeline Therapies- Ranibizumab, RFB002, Dexamethasone, pegaptanib sodium, AKB-9778, Aflibercept, Bevacizumab and others. Retinal Vein Occlusion Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Retinal Vein Occlusion Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Retinal Vein Occlusion Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Retinal Vein Occlusion Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Retinal Vein Occlusion: Overview Pipeline Therapeutics Therapeutic Assessment Late Stage Products (Phase III) KSI-301: Kodiak sciences Drug profiles in the detailed report….. Mid Stage Products (Phase II) 601: Sunshine Guojian Pharmaceutical Drug profiles in the detailed report….. Early Stage Products (Phase I) MHU650: Novartis Drug profiles in the detailed report….. Inactive Products Retinal Vein Occlusion Key Companies Retinal Vein Occlusion Key Products Retinal Vein Occlusion- Unmet Needs Retinal Vein Occlusion- Market Drivers and Barriers Retinal Vein Occlusion- Future Perspectives and Conclusion Retinal Vein Occlusion Analyst Views Retinal Vein Occlusion Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Yahoo
20-05-2025
- Yahoo
99 years behind bars for Leroy Page
May 19—LIMA — Leroy Page walked into an Allen County courtroom Monday morning wearing handcuffs, ankle chains and a smirk. He walked out less than an hour later to begin a 99-year prison sentence for kidnapping and assaulting two Allen County homeowners in October 2022. The smirk was still intact. Page was convicted Friday night by a 12-member jury on eight felony charges: having weapons under disability, improperly handling firearms in a motor vehicle, failure to comply with an order or signal of a police officer, aggravated burglary, two counts of kidnapping and two counts of felonious assault. He was sentenced Monday on three first-degree felonies, two each of second- and third-degree felonies and one fourth-degree felony. Sentences ranging from 12 months to 11 years were enhanced because five of the counts carried specifications labeling Page as a repeat violent offender due to his 2007 conviction in Allen County on a charge of voluntary manslaughter. The RVO specifications added 48 years of prison time to Page's already lengthy sentence. Judge Terri Kohlrieser ordered all sentences to be served consecutively "because no single prison term adequately reflects the harm caused" to two victims in the case. According to testimony that emerged during Page's trial, the events of Oct. 30, 2022, began when officers with the Lima Police Department stopped a vehicle for driving without adequate tail lights. Page was a rear-seat passenger in that vehicle. When officers removed the driver from the Jeep, Page leaped into the driver's seat and sped off at speeds that topped 120 mph. He crashed in a field near the intersection of West Elm Street and Fraunfelter Road near the home of Benjamin and Dianna Shelton. The Sheltons testified that Page broke into their home and terrorized them for several hours before demanding they drive him to a Shawnee Township location. Dianna Shelton addressed Page in court on Monday, saying a scar on her lip is a constant reminder of the terror she endured. "Cowards beat innocent, defenseless women," she said. "You are a coward. You're a violent criminal and will always be one. I hope you spend the rest of your life in a cage." At trial, Shelton told jurors she suffered multiple facial fractures, a broken nose, a severely lacerated lip and other injuries at the hands of Page. Jurors viewed photos taken at a Lima hospital that showed the bruising and swelling the woman suffered in the attack. She said Page struck her and her husband repeatedly over a span of several hours before forcing them to drive him to the intersection of Breese and Yoakam roads in Shawnee Township, near what police reportedly knew to be Page's residence. Page, 34, served as his own attorney throughout the trial. He plans to appeal his conviction and sentence. Featured Local Savings
Agriland
06-05-2025
- Health
- Agriland
DAFM data shows more TB reactors identified in Cork than any other county
Regional veterinary offices in Cork North and Cork South identified more bovine tuberculosis (TB) reactors over a 12 month rolling average to the end of the first quarter (Q1) of 2025, compared to any other county, according to latest figures from the Department of Agriculture, Food, and the Marine (DAFM). The Cork North regional veterinary office identified 3,336 rectors to the end of Q1 2025 while the Cork South regional veterinary office identified 3,917 reactors. In comparison, the Dublin regional veterinary office identified 219 based on a 12 month rolling average number of reactors. Overall, according to the latest statistics from DAFM, 41,780 TB reactors were identified by regional veterinary offices throughout the country to the end of Q1 2025. Regional Veterinary Office Number of Reactors Q1 2024 Q1 2025 Carlow RVO 146 148 Cavan RVO 1,225 1,407 Clare RVO 1,165 1,310 Cork North RVO 3,122 3,336 Cork South RVO 3,220 3,917 Donegal RVO 425 426 Dublin RVO 189 219 Galway RVO 1,296 2,172 Kerry RVO 1,841 2,735 Kildare RVO 504 526 Kilkenny RVO 1,528 2,028 Laois RVO 1,309 1,252 Leitrim RVO 298 419 Limerick RVO 1,550 1,908 Longford RVO 464 971 Louth RVO 371 417 Mayo RVO 575 886 Meath RVO 1,687 2,609 Monaghan RVO 1,349 1,585 Offaly RVO 601 939 Roscommon RVO 409 677 Sligo RVO 334 661 Tipperary North RVO 1,571 4,003 Tipperary South RVO 1,117 2,002 Waterford RVO 558 1,346 Westmeath RVO 483 1,175 Wexford RVO 996 955 Wicklow East RVO 997 751 Wicklow West RVO 1,002 1,000 National 30,332 41,780 Source: DAFM (April 2025) TB The Minister for Agriculture, Food and the Marine, Martin Heydon, plans to hold what he has described as a stakeholder summit this Thursday (May 8) to discuss a 'reset of the TB programme'. The minister said this is 'aimed at addressing deteriorating TB disease levels'. DAFM has outlined that TB disease levels in recent years have increased significantly. Herd incidence has increased from 4.31% in 2022 to 6.04% in 2024, a 36% increase in the number of herds restricted between 2022 and 2024, according to its analysis. Minister Heydon has acknowledged that 'an increasing number of farm families are facing the emotional and financial hardship of a TB breakdown'. In response to a parliamentary question recently tabled by the Fianna Fáil TD for Tipperary North, Ryan O'Meara, the minister said that 'as the spread of this disease is multi-factorial, we are fighting it on all fronts'. 'The TB programme in each county focuses on multiple factors, including local disease spread, contiguous programmes, gamma interferon testing, cleansing and disinfection, testing compliance, and swift isolation and removal of reactors and wildlife,' he stated. Minister Heydon said the 'ultimate aim is to control and eventually eradicate TB from the national herd'.
Associated Press
16-04-2025
- Business
- Associated Press
LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation
Exemption from the $5.1 million repayment obligation strengthens LAVA's balance sheet Underscores focus on cost curtailment and strategic option evaluation UTRECHT, The Netherlands and PHILADELPHIA, April 16, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, 'LAVA,' 'the Company'), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that the Netherlands Enterprise Agency (Rijksdienst voor Ondernemend Nederland, RVO) granted a full waiver of the final payment obligation related to the Innovation Credit, in the amount of $5.1 million. 'As part of LAVA's ongoing strategic review, we have implemented a targeted cost optimization initiative to enhance operational efficiency and financial flexibility,' said Steve Hurly, Chief Executive Officer of LAVA. 'Securing the $5.1 million repayment waiver is a significant milestone in this effort. This waiver strengthens our balance sheet by eliminating this outstanding debt obligation. We are grateful for the opportunity to work with the RVO and be part of the Innovation Credit program.' The Netherlands Enterprise Agency (Rijksdienst voor Ondernemend Nederland, RVO) Innovation Credit provides financing in the form of an interest-bearing loan to support the development of innovative programs according to defined criteria. LAVA was awarded a Netherlands Innovation Credit in 2019 related to the development of LAVA-051 and pledged certain assets of that project, including certain intellectual property (IP), as a guarantee. About LAVA Therapeutics LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company focused on advancing its proprietary Gammabody® platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid tumors and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell anti-tumor effector functions upon cross-linking to tumor-associated antigens. LAVA's pipeline includes three internal and partnered clinical-stage bispecific gamma-delta T cell engagers for the treatment of solid tumor and hematological cancers including LAVA 1266, targeting CD123+ cancers (ACTRN12624001214527); PF-08046052, targeting EGFR (NCT05983133); and JNJ-89853413, targeting hematological cancers (NCT06618001). The pipeline also includes preclinical programs. For more information on LAVA, please visit our website at or follow us on LinkedIn, X, and YouTube. Gammabody® is a registered trademark of LAVA Therapeutics N.V. LAVA's Cautionary Note on Forward-Looking StatementsCONTACTS Investor Relations [email protected] LifeSci Advisors (IR/Media) Joyce Allaire [email protected]
Yahoo
16-04-2025
- Business
- Yahoo
LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation
Exemption from the $5.1 million repayment obligation strengthens LAVA's balance sheet Underscores focus on cost curtailment and strategic option evaluation UTRECHT, The Netherlands and PHILADELPHIA, April 16, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, 'LAVA,' 'the Company'), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that the Netherlands Enterprise Agency (Rijksdienst voor Ondernemend Nederland, RVO) granted a full waiver of the final payment obligation related to the Innovation Credit, in the amount of $5.1 million. 'As part of LAVA's ongoing strategic review, we have implemented a targeted cost optimization initiative to enhance operational efficiency and financial flexibility,' said Steve Hurly, Chief Executive Officer of LAVA. 'Securing the $5.1 million repayment waiver is a significant milestone in this effort. This waiver strengthens our balance sheet by eliminating this outstanding debt obligation. We are grateful for the opportunity to work with the RVO and be part of the Innovation Credit program.' The Netherlands Enterprise Agency (Rijksdienst voor Ondernemend Nederland, RVO) Innovation Credit provides financing in the form of an interest-bearing loan to support the development of innovative programs according to defined criteria. LAVA was awarded a Netherlands Innovation Credit in 2019 related to the development of LAVA-051 and pledged certain assets of that project, including certain intellectual property (IP), as a guarantee. About LAVA Therapeutics LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company focused on advancing its proprietary Gammabody® platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid tumors and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell anti-tumor effector functions upon cross-linking to tumor-associated antigens. LAVA's pipeline includes three internal and partnered clinical-stage bispecific gamma-delta T cell engagers for the treatment of solid tumor and hematological cancers including LAVA 1266, targeting CD123+ cancers (ACTRN12624001214527); PF-08046052, targeting EGFR (NCT05983133); and JNJ-89853413, targeting hematological cancers (NCT06618001). The pipeline also includes preclinical programs. For more information on LAVA, please visit our website at or follow us on LinkedIn, X, and YouTube. Gammabody® is a registered trademark of LAVA Therapeutics N.V. LAVA's Cautionary Note on Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are 'forward-looking statements'. Words such as 'anticipate', 'believe', 'could', 'will', 'may', 'expect', 'should', 'plan', 'intend', 'estimate', 'potential', 'suggests', and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on LAVA's expectations and assumptions as of the date of this press release and are subject to various risks and uncertainties that may cause actual results to differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements relating to LAVA's initiatives to increase cost optimization and efficiencies. Many factors, risks and uncertainties may cause differences between current expectations and actual results, including, among other things, LAVA's ability to leverage its initial programs to develop additional product candidates using its Gammabody® platform, the failure of LAVA's collaborators to support or advance collaborations or LAVA's product candidates, the timing and results of LAVA's research and development programs and preclinical and clinical trials, the possibility that clinical trials may fail to establish sufficient efficacy, the risk that adverse events or safety signals may occur in clinical trials, the risk that results obtained in preclinical studies or clinical trials to date may not be indicative of results obtained in ongoing or future trials, the risk that adverse regulatory actions or other setbacks could occur in clinical trials even after promising results in earlier clinical trials or preclinical studies, LAVA's ability to obtain regulatory approval for and commercialize its product candidates, LAVA's ability to identify any strategic alternatives or if so identified, be able to consummate any such transactions on terms acceptable to LAVA and its shareholders, and the risk that setbacks in development could occur as a result of the difficulty and uncertainty of pharmaceutical product development and other factors. There may be adverse effects on LAVA's business condition and results from general economic and market conditions and overall fluctuations in the United States and international credit and financial markets, including as a result of inflation, heightened interest rates, recent and potential future pandemics and other health crises, and hostilities, including the conflict in Ukraine and the conflict in the Middle East. These and other risks are described in greater detail under the caption 'Risk Factors' in LAVA's most recent Annual Report on Form 10-K and other filings LAVA makes with the U.S. Securities and Exchange Commission. LAVA assumes no obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, change in expectations or otherwise, except as otherwise required by law. CONTACTSInvestor Relationsir@ LifeSci Advisors (IR/Media)Joyce AllaireJallaire@ in to access your portfolio
